drugset

drugset / Trial / NCT03200847

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

NCT03200847 ↗

Phase 1/2 Completed 26 enrolled University of Colorado, Denver Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.

Timeline

Start: 2017-10-31
Primary completion: 2022-07-20
Completion: 2022-10-19

Publications

Background Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 Apr 3;29(7):1209-1219. doi: 10.1158/1078-0432.CCR-22-2495.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	200 mg	—
Subject	Tretinoin	Small molecule	150 mg/m2	Oral

Indications